May 29 2024 26 mins
Brendon Neuen, MBBS, PhD, joins hosts to discuss the landmark FLOW trial and its implications on the future of chronic kidney disease management as well as other compelling data surrounding semaglutide from the 61st European Renal Association Congress.
Key Highlights:
00:00 - Intro
01:12 - ERA Recap
03:06 - FLOW Background
05:20 - FLOW Results
06:56 - FLOW Reaction (Neuen)
09:13 - Semaglutide Mortality Benefit
12:43 - Semaglutide 2.4 in CKD
17:30 - Implementation Science
22:30 - Management Approach
Key Highlights:
00:00 - Intro
01:12 - ERA Recap
03:06 - FLOW Background
05:20 - FLOW Results
06:56 - FLOW Reaction (Neuen)
09:13 - Semaglutide Mortality Benefit
12:43 - Semaglutide 2.4 in CKD
17:30 - Implementation Science
22:30 - Management Approach